Julie D. Kizlik, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 18901 Lake Shore Blvd, Euclid, OH 44119 Phone: 216-531-9000 |
News Archive
Researchers at Washington University School of Medicine in St. Louis have identified a way to trigger reproduction in the laboratory of clusters of human cells that make insulin, potentially removing a significant obstacle to transplanting the cells as a treatment for patients with type 1 diabetes.
In the first molecular genetic study of families with a history of both language impairment and autism, scientists may have uncovered a shared origin for the two conditions, an important step toward explaining why some cases of autism are accompanied by language difficulties and others are not. The study, a collaboration of The Research Institute at Nationwide Children's Hospital with experts at Rutgers University, indicates that a disorder called specific language impairment—one of the most common developmental delays in children—may be caused by the same genetic variants that lead to language difficulties in some children with autism.
Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University; Marc A. Pfeffer, M.D., Dzau professor of medicine at Harvard Medical School; John W. Newcomer, M.D., executive vice dean of FAU's College of Medicine and interim vice president for research at FAU; Paul S. Jellinger, M.D., affiliate professor at the University of Miami Miller School of Medicine; and Alan Garber, M.D., Ph.D., professor of medicine at Baylor, have published a commentary in the American Journal of Managed Care titled "Treatment of Diabetes Mellitus: The Urgent Need for Multifactorial Interventions."
New research published online today in Blood, the Journal of the American Society of Hematology (ASH), concludes that a blood clot in an abdominal vein may be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer.
Patient Safety Technologies, Inc. announced today the closing of a $6.0 million private placement financing. The new capital will primarily be used to fund working capital and the continued growth of the Company.
› Verified 4 days ago